GLPwatch
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
NCT02059564 · Unknown status
Last updated 2026-05-28This clinical trial tests the safety and effects of LAPS-Exendin, a new medication, in adults with type 2 diabetes to understand how it is processed in the body.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 44 people Planned (estimated).
Who can join Ages 18–70 · all sexes
Timeline Started 2013-12 · est. completion 2014-12
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT02059564 ↗
Description as written by the study sponsor.
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus
Treatments tested
- HM11260C also known as LAPS-Exendin-4 Drug
doses of 6 mg, 16 mg
- Placebo also known as Normal saline solution Drug
Normal saline solution
- Victoza also known as Liraglutide Drug
doses of 1.8 mg
| Main thing measured | PK profile of acetaminophen |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Conditions studied | Diabetes Mellitus |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02059564 ↗